ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction
BioSpace
While survodutide's 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma's drug achieved "impressive" fat loss, according to BMO Capital Markets.
pharminent
June 8, 2026 (Last updated: June 8, 2026)
BioSpace
While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.
